Related coverage linked through entity extraction aliases.
Jul 03, 2026
Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
Jun 19, 2026
A $9 million grant from ASAP and The Michael J. Fox Foundation funds an Indiana University-led study on immune cell exhaustion in Parkinson's disease, aiming to develop personalized immunotherapies. The multi-institutional team will map immune system changes to uncover biomarkers and explain disease heterogeneity. Advances in proteomics are also enabling molecular subtyping and precision medicine across neurological disorders.
Jun 19, 2026
Clinical trials are offering new options for cancer patients, with some achieving long-term survival even with advanced disease. Precision medicine programs are expanding access to these trials by identifying patients with specific tumor mutations, reshaping oncology care.
May 26, 2026
The global radiopharmaceuticals market is projected to reach $12.8B–$21.8B by 2033–2036, driven by cancer therapy demand. Oncology accounts for over 50% of applications, Technetium-99m dominates radioisotopes, and Asia-Pacific leads growth.
Apr 20, 2026
The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.
Apr 18, 2026
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
Apr 06, 2026
Illuminate 3.0 brought global and Indian oncology experts to Mumbai for a three-day townhall on precision oncology, immunotherapy, cellular therapies and cancer vaccines. Discussions covered CAR-T cell therapy, multi-cancer early detection and access to novel drugs in India.
Apr 02, 2026
Genomic technologies including whole-genome sequencing and polygenic risk scores are advancing precision medicine for neurodegenerative diseases like Alzheimer's and Parkinson's. Research reveals complex gene interactions in conditions like PTEN hamartoma tumor syndrome and sex-specific metabolic signatures in Alzheimer's disease. The integration of genomics with molecular neurobiology offers potential for more accurate diagnosis and treatment.
Mar 30, 2026
The artificial intelligence in drug discovery market is projected to grow from USD 3.25 billion in 2026 to USD 10.29 billion by 2031, representing a 25.94% CAGR. AI technologies are accelerating drug discovery timelines, reducing costs, and improving success rates through advanced analytics and machine learning. North America leads market adoption while Asia-Pacific emerges as a high-growth region driven by expanding biotechnology sectors.
Mar 23, 2026
The global orphan drugs market is projected to grow from $223.76 billion in 2023 to $486.51 billion by 2032, with North America leading at 38% market share. Over 500 orphan drugs are approved with more than 800 candidates in clinical trials, driven by regulatory incentives and major pharmaceutical company investments in rare disease therapies.
Mar 14, 2026
Healthcare leaders report precision medicine is becoming a clinical standard as AI tools emerge as "digital co-workers" and breakthroughs in biomarkers move beyond specialized oncology into primary care settings.
Mar 02, 2026
The pharmaceutical industry is experiencing recovery driven by innovation in drug development, aggressive M&A activity, and expansion of drug development services. The sector faces both opportunities and headwinds including pipeline setbacks and regulatory pressures.
Feb 26, 2026
Three new market reports project significant expansion in pharmaceutical R&D outsourcing, the U.S. pharmaceutical market, and biotechnology services outsourcing, driven by innovation, aging populations, and cost efficiency needs through 2035.
Feb 13, 2026
The global epigenetics drugs and diagnostic technologies market is projected to reach USD 79.03 billion by 2035, while the genomics in cancer care market is expected to hit USD 108.69 billion, driven by precision medicine advances and AI integration.
